# A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

> **NCT04985266** · PHASE2 · RECRUITING · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 1100 (estimated)

## Conditions studied

- ER+ Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Palbociclib 125Mg Tab
- **DRUG:** Fulvestrant injection
- **DRUG:** Tamoxifen
- **DRUG:** Letrozole
- **DRUG:** Exemestane
- **DRUG:** Anastrozole

## Key facts

- **NCT ID:** NCT04985266
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-30
- **Primary completion:** 2027-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2024-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04985266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04985266, "A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04985266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*